Results 31 to 40 of about 28,830 (248)

PCSK9 induces a pro-inflammatory response in macrophages [PDF]

open access: yes, 2018
Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and released by SMCs within the atherosclerotic plaque but its
Adorni, Maria Pia   +12 more
core   +3 more sources

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

open access: yes, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah   +13 more
core   +1 more source

The kunitz domain protein BLI-5 plays a functionally conserved role in cuticle formation in a diverse range of nematodes [PDF]

open access: yes, 2010
The cuticle of parasitic nematodes performs many critical functions and is essential for proper development and for protection from the host immune response.
Antony P. Page   +43 more
core   +1 more source

Small molecule proprotein convertase inhibitors for inhibition of embryo implantation. [PDF]

open access: yesPLoS ONE, 2013
Uterine proprotein convertase (PC) 6 plays a critical role in embryo implantation and is pivotal for pregnancy establishment. Inhibition of PC6 may provide a novel approach for the development of non-hormonal and female-controlled contraceptives.
Huiting Ho   +8 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review

open access: yesFrontiers in Cardiovascular Medicine, 2022
The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation ...
Na-Qiong Wu, Hui-Wei Shi, Jian-Jun Li
doaj   +1 more source

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]

open access: yesPharmacological Reviews, 2017
The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Nabil G, Seidah   +4 more
openaire   +2 more sources

Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]

open access: yes, 2019
The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio   +3 more
core   +1 more source

Association of obesity risk SNPs in PCSK1with insulin sensitivity and proinsulin conversion [PDF]

open access: yes, 2010
Background Prohormone convertase 1 is involved in maturation of peptides. Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
Martin Heni   +9 more
core   +2 more sources

Testicular Germ Cell Tumours and Proprotein Convertases

open access: yesCancers, 2022
Testicular Germ Cell Tumours (TGCT) are widely considered a “curable cancer” due to their exceptionally high survival rate, even if it is reduced by many years after the diagnosis due to metastases and relapses. The most common therapeutic approach to TGCTs has not changed in the last 50 years despite its multiple long-term side effects, and because it
Aitziber Velado-Eguskiza   +4 more
openaire   +3 more sources

Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:A systematic review and meta-analysis [PDF]

open access: yes, 2019
Background: To evaluate the effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on major adverse cardiovascular events (MACE).Methods: Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in ...
Du, Heyue   +17 more
core   +3 more sources

Home - About - Disclaimer - Privacy